LPL and hypertriglyceridemia: Mangiferin is able to prevent or correct hypertriglyceridemia by modulating gene expression and favoring lipid catabolism by suppressing TAG-producing genes (SREBP1c, DGAT2 (diglyceride acyltransferase) and MTTP (microsomal triglyceride transfer protein)) and favoring lipid-catabolizing genes (PPARα, CPT1, LPL (lipoprotein lipase) and CD36).